Findings seen across body mass index groups. (HealthDay News) — Metformin use is associated with lower risks for dementia and all-cause mortality across body mass index (BMI) groups in patients ...

Hispanic, Black non-Hispanic, White non-Hispanic adults more likely to use GLP-1 RA injectables than Asian non-Hispanics. (HealthDay News) — In 2024, 26.5 percent of adults with diagnosed ...

Pembrolizumab plus lenvatinib is currently a standard of care for clear-cell renal cell carcinoma (RCC), so investigators assessed the combination for non-clear-cell RCC.

There is decreased risk for MACE and all-cause mortality in dialysis-dependent patients with ASCVD who are treated with statins.

Age and hematologic disease length are positive predictors for CKD; acute lymphoblastic leukemia is a negative predictive factor.

Patients who regularly use antiemetic medication, such as for nausea from chemotherapy, appear at increased risk for chronic kidney disease.

The FDA has approved an expanded indication of the IV formulation of Avtozma to include the treatment of CRS in patients 2 years of age and older.

The ArteraAI Prostate Test is intended to assist clinicians and patients with risk-based decisions in localized prostate cancer.

Findings seen among both those previously treated for cancer and cancer-naive people. (HealthDay News) — Most individuals living in underserved communities believe that dermatologic side effects ...

46.4 percent said they would accept one or more missing vaccines if they could be provided during their ED visit.

Magnetic stimulation plus bladder training and TTNS plus bladder training are both more effective than bladder training alone.

Research links environmental exposures to CKD development and progression. Here’s what clinicians and patients need to know.